Treating enlarged heart and HCM

Livagen

Experimental research performed by Vladimir khavinson shows that Livagen (a peptide bio-regulator) can prevent the onset of HCM, even in those who are genetically predisposed to developing the conditiong.

The involvement of lymphocytes in cardiac health, particularly concerning conditions like hypertrophic cardiomyopathy shows that there is an intricate relationship between the immune system and heart function. This is one of the reasons thymalin (which we will discuss soon) has so many benefits. In HCM and atherosclerosis, the dysregulation of chromatin structure in lymphocytes is associated with pathogenic changes. This can affect gene expression patterns that are important for maintaining heart health. Abnormal chromatin configuration can lead to the silencing of protective genes and the activation of pro-inflammatory pathways, which is a key hallmark of cardiac remodeling and dysfunction.

The decondensation of chromatin in lymphocytes essentially allows for the release of genes that can mitigate inflammation and reduce scarring (fibrosis) in heart tissues. Livagen's mechanism of action promote this chromatin remodeling, enhancing the expression of beneficial genes that combat inflammation and support cardiac repair. Livagen in particular has been shown in Russian research to help inhibit the activation of fibroblasts, which are cells responsible for scar formation, by modulating lymphocyte activity. This can be particularly beneficial in preventing the progression of HCM, where excessive fibrosis can lead to obstructive pathologies and remodeling of the heart

For individuals genetically predisposed to HCM, Livagen could be a useful tool for treatment and prevention for those prone to developing HCM. Livagen may also be very useful following cardiac events, such as heart attacks and for attentuating heart failure. Some of you may be familiar with my friend Ryan who reverse stage 3 heart failure. This was one of the peptides in his stack.

Cardiogen

Cardiogen is another peptide bioregulator for the heart. Its effects on cardiomyocytes (heart muscle cells) and fibroblasts (cells involved in scar formation) are particularly relevant for HCM, especially concerning cardiac remodeling as well as conditions like heart failure.

Cardiogen promotes the proliferation of cardiomyocytes, which is essential for repairing and regenerating heart tissue. This is particularly important because the heart has poor capacity for self-regeneration and healing. By stimulating specific growth factors and signaling pathways, Cardiogen facilitates the transition of cardiomyocytes from a resting state to an active cell cycle, promoting their growth and division.

Cardiogen appears to inhibit the proliferation and activation of fibroblasts predominantly. This is crucial because excessive fibroblast activity can lead to fibrosis, characterized by scar tissue formation that compromises heart function.

By reducing fibroblast activity, Cardiogen helps maintain a healthier balance in the extracellular matrix which is vital for normal cardiac structure and performance. Especially in pressure overload models with concentric hypertrophy, which increases wall thickness and decreases in chamber size

Because cardiogen has been shown to decrease the expression of p53, a protein commonly associated with apoptosis (programmed cell death). Elevated levels of p53 can lead to increased cardiomyocyte death, particularly under stress conditions.

By selectively ly modulating p53 activity in select tissues (that’s the key), Cardiogen may help protect cardiomyocytes from apoptosis, thereby preserving the functional mass of the heart.

Urolithin A

Urolithin A is a metabolite derived from ellagitannins, which are found in various fruits, especially pomegranates. Some papers have shown that urolithin a is particularly useful for inducing mitophagy and protecting against diabetic cardiomyopathy.

Mitophagy is a selective form of autophagy that targets damaged mitochondria for degradation. UA promotes this process, helping to maintain mitochondrial health. UA activates key signaling pathways such as the AMPK and SIRT1 pathways as well. AMPK activation enhances mitochondrial biogenesis (proliferation of new mitochondria) and function, while SIRT1 boosters the cellular stress responses

UA enhances mitochondrial respiration and ATP production. This is vital because impaired mitochondrial function is a hallmark of diabetic cardiomyopathy, leading to energy deficits in cardiac tissues.

In both in vivo and in vitro models, UA has protective effects on cardiomyocytes. By promoting cell survival pathways and reducing apoptosis like cardiogen, UA can help preserve cardiac function in diabetic conditions. As an extension, I believe UA could likely be useful for cardiomyopathy of varying genesis and etiology. This would make sense considering that all forms of cardiomyopathy exhibit identical features related to cardiac remodeling, mitochondrial dysfunction and immune dysregulation.

Sourcing for peptides —- canlabs international

https://canlabintl.com

Possible theoretic Dosing for bio-regulators based on available scientific literature (not medical advice)—

1-2mg for 10-20 days, 2-3x a year for prevention or maintiance of health.

5-10mg for 10-20 days, once every 2-3 months for the treatment and management of existing pathology

Bio-regulator peptides can also be found in capsule form as well. Brand doesn’t matter much as they are mostly the same. Although it may be easier to find the capsule version of cardiogen under a different name: chelohart.

Note — capsules can be useful. But not for serious conditions, these usually require higher doses of injectables.

Dosing for UA — 500mg for 4-6 months

Timeline nutrition or DoNotAge brand